HRMY
Income statement / Annual
Last year (2024), Harmony Biosciences Holdings, Inc.'s total revenue was $714.73 M,
an increase of 22.80% from the previous year.
In 2024, Harmony Biosciences Holdings, Inc.'s net income was $145.49 M.
See Harmony Biosciences Holdings, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$714.73 M |
$582.02 M |
$437.86 M |
$305.44 M |
$159.74 M |
$6.00 M |
$0.00 |
| Cost of Revenue |
$156.82 M
|
$121.24 M
|
$83.48 M
|
$55.52 M
|
$27.74 M
|
$1.58 M
|
$184,000.00
|
| Gross Profit |
$557.92 M
|
$460.79 M
|
$354.37 M
|
$249.92 M
|
$132.00 M
|
$4.42 M
|
-$184,000.00
|
| Gross Profit Ratio |
0.78
|
0.79
|
0.81
|
0.82
|
0.83
|
0.74
|
0
|
| Research and Development Expenses |
$145.83 M
|
$76.06 M
|
$70.89 M
|
$30.37 M
|
$19.45 M
|
$69.60 M
|
$12.37 M
|
| General & Administrative Expenses |
$110.35 M
|
$95.29 M
|
$84.02 M
|
$63.91 M
|
$39.75 M
|
$36.41 M
|
$12.21 M
|
| Selling & Marketing Expenses |
$110.92 M
|
$97.40 M
|
$79.29 M
|
$68.12 M
|
$55.82 M
|
$44.32 M
|
$16.86 M
|
| Selling, General & Administrative Expenses |
$221.27 M
|
$192.69 M
|
$163.30 M
|
$132.03 M
|
$95.57 M
|
$80.73 M
|
$29.07 M
|
| Other Expenses |
$0.00
|
$0.00
|
$169,000.00
|
$16,000.00
|
-$3.07 M
|
$0.00
|
$0.00
|
| Operating Expenses |
$367.09 M
|
$268.76 M
|
$234.19 M
|
$162.39 M
|
$115.02 M
|
$150.32 M
|
$41.44 M
|
| Cost And Expenses |
$523.91 M
|
$389.99 M
|
$317.67 M
|
$217.91 M
|
$142.76 M
|
$151.90 M
|
$41.44 M
|
| Interest Income |
$18.54 M
|
$14.73 M
|
$3.13 M
|
$223,000.00
|
$28.22 M
|
$6.07 M
|
$0.00
|
| Interest Expense |
$17.50 M
|
$23.76 M
|
$15.67 M
|
$23.97 M
|
$28.22 M
|
$6.07 M
|
$0.00
|
| Depreciation & Amortization |
$24.11 M
|
$24.36 M
|
$23.39 M
|
$18.84 M
|
$10.24 M
|
$3.21 M
|
$184,000.00
|
| EBITDA |
$233.41 M |
$221.51 M |
$143.57 M |
$106.37 M |
$1.51 M |
-$142.69 M |
-$41.26 M |
| EBITDA Ratio |
0.33
|
0.38
|
0.27
|
0.29
|
0.09
|
-23.8
|
0
|
| Operating Income Ratio |
0.27
|
0.33
|
0.27
|
0.22
|
0.02
|
-24.34
|
0
|
| Total Other Income/Expenses Net |
$978,000.00
|
-$18.63 M
|
-$15.50 M
|
-$50.10 M
|
-$53.93 M
|
-$6.07 M
|
$1.54 M
|
| Income Before Tax |
$191.80 M
|
$173.40 M
|
$104.69 M
|
$37.43 M
|
-$36.94 M
|
-$151.98 M
|
-$39.90 M
|
| Income Before Tax Ratio |
0.27
|
0.3
|
0.24
|
0.12
|
-0.23
|
-25.35
|
0
|
| Income Tax Expense |
$46.31 M
|
$44.54 M
|
-$76.78 M
|
$2.83 M
|
$14.91 M
|
$6.07 M
|
$1.54 M
|
| Net Income |
$145.49 M
|
$128.85 M
|
$181.47 M
|
$34.60 M
|
-$51.86 M
|
-$158.05 M
|
-$39.90 M
|
| Net Income Ratio |
0.2
|
0.22
|
0.41
|
0.11
|
-0.32
|
-26.36
|
0
|
| EPS |
2.56 |
2.17 |
3.07 |
0.6 |
-0.91 |
-2.48 |
-0.81 |
| EPS Diluted |
2.51 |
2.13 |
2.97 |
0.58 |
-0.91 |
-2.48 |
-0.81 |
| Weighted Average Shares Out |
$56.89 M
|
$59.47 M
|
$59.17 M
|
$57.53 M
|
$56.89 M
|
$63.68 M
|
$49.24 M
|
| Weighted Average Shares Out Diluted |
$57.87 M
|
$60.37 M
|
$61.10 M
|
$59.21 M
|
$56.89 M
|
$63.68 M
|
$49.24 M
|
| Link |
|
|
|
|
|
|
|
